Seven months ago, Novo Nordisk fired nearly all 250 employees in its cell therapy division and abandoned three programmes that represented some of the most scientifically ambitious work in the company's pipeline.
On Monday, one of those programmes found a new home, and the circumstances of the rescue tell a pointed story about how the pharmaceutical industry's priorities are being distorted by the economics of obesity.
Cellular Intelligence, a Boston-based AI biotech startup backed by Meta chief executive Mark Zuckerberg, has acquired global rights to STEM-PD, Novo Nordisk's clinical-stage cell therapy for Parkinson's disease.
The treatment takes donor stem cells, transforms them into dopamine-producing neurons, the brain cells that are progressively destroyed by Parkinson's, and transplants them directly into patients' brains. It is currently in a first-in-human Phase 1/2 trial and has received FDA Fast Track Designation.
The therapy is not incremental. Existing Parkinson's treatments manage symptoms by supplementing dopamine levels chemically, but they do not replace the neurons that produce it, and their effectiveness diminishes over time as the disease progresses. STEM-PD aims to reverse the underlying damage by physically restoring the cells the brain has lost. If it works, it would be among the first disease-modifying treatments for a condition that affects nearly 12 million people worldwide and has no cure.
Novo Nordisk decided it could not afford to find out.
The Danish drugmaker shut down its cell therapy unit in October 2025 as part of a sweeping restructuring ordered by new chief executive Mike Doustdar, who replaced Lars Fruergaard Jorgensen after Novo's share price collapsed roughly 60% from its 2024 peak. The decline was driven by a single competitive failure: Eli Lilly's weight-loss drug tirzepatide was gaining market share against Novo's Wegovy, and investors punished the company for falling behind in what had become the most lucrative therapeutic category in the history of pharmaceuticals.
Doustdar's response was to narrow Novo's focus to diabetes and obesity, the company's core franchise, and shed everything else. The cell therapy programmes for Parkinson's, chronic heart failure and type 1 diabetes were all discontinued. The message was unambiguous: in a market where Wegovy alone generates tens of billions in annual revenue, experimental cell therapies that might not produce commercial returns for a decade are a distraction.
Cellular Intelligence believes the science is too good to abandon. The company, which describes itself as an "AI-native TechBio," plans to use its proprietary AI platform to compress the manufacturing and development timelines that have historically made cell therapies prohibitively expensive and difficult to scale. Cell replacement therapies have been plagued by problems of scalability, producibility and cost, chief executive Micha Breakstone told Fierce Biotech, and those are precisely the areas the company's AI tools are designed to address.
The platform can make minor adjustments to stem cell processing that produce outsized improvements in cell viability and consistency, Breakstone said, potentially solving the manufacturing bottleneck that has kept cell therapies confined to small, expensive clinical trials rather than large-scale commercial production.
Cellular Intelligence is expanding into Copenhagen with a 26-person team that includes former Novo researchers who worked on STEM-PD before the shutdown. New chief medical officer Nuno Mendonca, who previously held senior neuroscience roles at AbbVie and Novartis, said the company plans to launch a Phase 2 study by the end of the year.
Novo Nordisk retains an equity stake in Cellular Intelligence and is eligible for milestone payments and royalties if STEM-PD reaches the market, a structure that allows the Danish company to benefit from any eventual success without bearing the development costs. Financial terms were not disclosed.
Related reading
- NVIDIA names Suzanne Nora Johnson to board
- Nvidia's top AI server hits $1 million in China as US crackdown on chip smuggling doubles prices
- Google in talks with Marvell to develop two new AI chips as it builds multi-supplier TPU strategy
The deal is a microcosm of a broader pattern in the pharmaceutical industry. The obesity market is so large and so profitable that it is warping capital allocation across the entire sector, pulling resources away from difficult, long-horizon science in favour of drugs that can generate near-term revenue in a market where demand vastly exceeds supply. Novo is not the only company making this calculation, but it is the one that shut down a programme capable of replacing lost brain cells in order to sell more weight-loss injections.
For the 12 million people living with Parkinson's disease, the question is whether a Zuckerberg-backed AI startup with a 26-person Copenhagen team can succeed where one of the world's largest pharmaceutical companies decided it was not worth trying.
The recap
- Novo Nordisk agrees to sell Parkinson's cell therapy to Cellular Intelligence
- Therapy is undergoing early and midstage clinical trials
- Novo Nordisk will take equity stake and may receive future payments
